What is Medullary Thyroid Cancer Phase 2 study GI-6207?

Category: Others

false

NCT01856920 is a Phase 2 Study of GI-6207 in subjects With Recurrent Medullary Thyroid Cancer. Other study ID number include GI-6207-02.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 1
Mild 0
None 0

Commonly reported side effects and conditions associated with Medullary Thyroid Cancer Phase 2 study GI-6207

Side effect Patients
Cold sweat 1
Diarrhea 1
Projectile vomiting 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 0
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 1
Not specified 0
Last updated:
There are no evaluations for Medullary Thyroid Cancer Phase 2 study GI-6207.